PHR:NYE-Phreesia Inc (USD)

COMMON STOCK | Health Information Services |

Last Closing

USD 23.59

Change

0.00 (0.00)%

Market Cap

N/A

Volume

1.13M

Analyst Target

USD 30.11
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-22 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap
SOLV Solventum Corp.

N/A

USD 10.78B
DOCS Doximity Inc

N/A

USD 7.30B
WEAV Weave Communications Inc

N/A

USD 0.86B
MPLN MultiPlan Corporation

N/A

USD 0.17B
AMWL American Well Corp

N/A

USD 0.15B
OWLT Owlet Inc

N/A

USD 0.07B
TDOC Teladoc Inc

N/A

N/A
FOXO FOXO Technologies Inc.

N/A

N/A
EVH Evolent Health Inc

N/A

N/A
VEEV Veeva Systems Inc Class A

N/A

N/A

ETFs Containing PHR

W311:XETRA HAN-GINS Indxx Healthcare.. 1.18 % 0.00 %

N/A

USD 0.02B
W311:F HAN-GINS Indxx Healthcare.. 1.18 % 0.00 %

N/A

USD 0.02B
WELL:PA HAN-GINS Indxx Healthcare.. 1.18 % 0.00 %

N/A

N/A
WELL:SW HAN-GINS Indxx Healthcare.. 1.17 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health Information Services) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1.90% 70% C- 31% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.90% 70% C- 24% F
Trailing 12 Months  
Capital Gain 32.83% 80% B- 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 32.83% 80% B- 78% C+
Trailing 5 Years  
Capital Gain -10.51% 50% F 32% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.51% 50% F 19% F
Average Annual (5 Year Horizon)  
Capital Gain 13.21% 80% B- 75% C
Dividend Return 13.21% 80% B- 70% C-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 68.15% 60% D- 12% F
Risk Adjusted Return 19.38% 70% C- 38% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector